News

Mercurna is proud to be a partner in NANEMIAR, a European collaborative project focused on developing next-generation nanomedicines for the targeted delivery of RNA therapeutics to the bone marrow.

Mercurna has been awarded funding through the Health~Holland SME Call for its project "PREDIKT-RNA - Peptide-REDirected Kidney Targeting for RNA-based treatment of renal inflammation." The project will be conducted in collaboration with Radboud university medical center (Radboudumc).

Mercurna is excited to announce the successful closing of its extended Pre‑Seed financing round, an important milestone that enables us to accelerate the development of our lead program, mCura1 and advance our proprietary kidney-targeted delivery platform.

To support its expanding ambitions, Mercurna, a pre-clinical-stage biotechnology company developing a platform for life-changing medicines based on messenger RNA (mRNA), has moved into a new, larger laboratory at the BioMatTech Campus in Nijmegen.

The Eurostars program, part of the Eureka network, supports high‑impact, collaborative innovation led by R&D‑driven SMEs. Receiving this award underscores both the scientific strength of Mercurna’s approach and the consortium’s potential to deliver breakthroughs that reshape the future of mRNA therapy for kidney diseases.

ORGESTRA is a four-year project funded by the EC HORIZON-MSCA-2023-DN-JD Grant Agreement No 101120108, coordinated by the University of Utrecht. The doctoral network consists of 14 partners from 7 European countries.